According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...

versus dupilumab (Dupixent, per its labeled dose) for atopic dermatitis. AbbVie said the study is the first head-to-head trial in atopic dermatitis assessing upadacitinib at a starting dose of 15 ...

LEO will also able to offer patients an alternative to the blockbuster Sanofi/Regeneron Pharmaceuticals drug Dupixent. Atopic dermatitis patients now have a new therapeutic option that comes as a ...

including atopic dermatitis (AD), in which it is considered the gold standard, says GlobalData, a data and analytics company. “Having Dupixent as the gold standard for AD, Sanofi has set a high ...

Dupixent (dupilumab) was the first biologic medicine to get approval for atopic dermatitis in 2017, and since then has grown sales to more than $2 billion last year, with Sanofi suggesting it ...

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...